Fortress Biotech Inc (NASDAQ:FBIO) – Investment analysts at FBR & Co issued their Q1 2017 earnings per share (EPS) estimates for Fortress Biotech in a report issued on Friday. FBR & Co analyst E. White anticipates that the brokerage will earn ($0.33) per share for the quarter. FBR & Co also issued estimates for Fortress Biotech’s Q2 2017 earnings at ($0.41) EPS, Q3 2017 earnings at ($0.42) EPS and Q4 2017 earnings at ($0.43) EPS.

Your IP Address:

Separately, Zacks Investment Research raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Tuesday, January 10th.

Shares of Fortress Biotech (NASDAQ:FBIO) opened at 3.76 on Monday. Fortress Biotech has a 1-year low of $1.88 and a 1-year high of $4.66. The firm’s 50-day moving average is $3.00 and its 200-day moving average is $2.67. The company’s market capitalization is $183.77 million.

An institutional investor recently raised its position in Fortress Biotech stock. State Street Corp increased its position in shares of Fortress Biotech Inc (NASDAQ:FBIO) by 14.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 340,390 shares of the biopharmaceutical company’s stock after buying an additional 42,649 shares during the period. State Street Corp owned about 0.70% of Fortress Biotech worth $919,000 as of its most recent SEC filing. Institutional investors own 14.63% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

5 Day Chart for NASDAQ:FBIO

Receive News & Ratings for Fortress Biotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc and related companies with's FREE daily email newsletter.